T. Hugh Jones  European Urology Supplements 

Slides:



Advertisements
Similar presentations
Sex Differences in Overweight & Obesity.
Advertisements

Adipose tissue dysfunction in obesity, diabetes, and vascular diseases by Gideon R. Hajer, Timon W. van Haeften, and Frank L.J. Visseren EHJ Volume ():
Samuel Yeung Shan Wong, Dicken C.C. Chan, Athena Hong, Jean Woo 
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Pascal Rischmann  European Urology Supplements 
Prostate Cancer 2008: Challenges in Diagnosis and Management
Management of Acute and Chronic Retention in Men
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction  Steven A. Kaplan,
The Correlation Between Metabolic Syndrome and Prostatic Diseases
Association between Smoking, Passive Smoking, and Erectile Dysfunction: Results from the Boston Area Community Health (BACH) Survey  Varant Kupelian,
Vascular biology of metabolic syndrome
Bladder Cancer: A Major Public Health Issue
Does Hypothalamic Inflammation Cause Obesity?
Male contraception Fertility and Sterility
Back to the Future: Introduction and Conclusions
Leptin, obesity, and liver disease
In and Out: Adipose Tissue Lipid Turnover in Obesity and Dyslipidemia
Adipose tissue and reproduction in women
Counselling the Prostate Cancer Patient
Laurent Boccon-Gibod  European Urology Supplements 
Volume 42, Issue 4, Pages (October 2002)
Volume 44, Issue 5, Pages (November 2003)
Relationship between Lower Urinary Tract Symptoms Frequency Assessed by the IPSS and Bothersomeness (SPI) among Men Older than 50 Years Old  P. Perrin,
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
An Update of Current Practice in Hypospadias Surgery
Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in.
Richard C. Harkaway  European Urology Supplements 
Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
Volume 50, Issue 5, Pages (November 2006)
Aging-related inflammation in osteoarthritis
Regarding “Prospective evaluation of postimplantation syndrome evolution on patient outcomes after endovascular aneurysm repair for abdominal aortic aneurysm” 
Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy  Bertrand Tombal, Richard Berges  European Urology.
Nat. Rev. Endocrinol. doi: /nrendo
Ian Milsom  European Urology Supplements 
The Importance of Testosterone Control in Prostate Cancer
Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice  Claus Roehrborn  European Urology.
Neal Shore  European Urology Supplements 
Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era  Faustino R. Pérez-López,
Testosterone Deficiency: A Common, Unrecognised Syndrome?
Christian Stief  European Urology Supplements 
Is Growth Hormone Resistance/IGF-1 Reduction Good for You?
Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders
In and Out: Adipose Tissue Lipid Turnover in Obesity and Dyslipidemia
Emmanuel Chartier-Kastler, Kate Davidson  European Urology Supplements 
A Cross-Sectional, Population-Based, Multinational Study of the Prevalence of Overactive Bladder and Lower Urinary Tract Symptoms: Results from the EPIC.
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Who Forms Stones and Why?
Prostate Cancer 2008: Challenges in Diagnosis and Management
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Banking on ATM as a new target in metabolic syndrome
Improving Flexibility and Quality of Life for Your Patients: A Must?
New Concepts in Epidemiology of Lower Urinary Tract Symptoms in Men
LUTS and Sexual Dysfunction: Implications for Management of BPH
Volume 24, Issue 20, Pages R988-R993 (October 2014)
The Impact of Nocturia on Health Status and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH) 
Does Testosterone Have a Role in Erectile Function?
Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer  Sten Holmäng  European Urology.
Joaquim Bellmunt  European Urology Supplements 
Classification of Mixed Incontinence
Obesity and vascular dysfunction
The Impact of Premature Ejaculation on Partners and Relationships
ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome  Lucas Bandeira Marchesan, B.Sc., Poli Mara Spritzer,
Emmanuel Chartier-Kastler, Andrea Tubaro  European Urology Supplements 
Diagnosis and Management of Cryptorchidism
Ann Marie Schmidt, Kathryn J. Moore  Cell Metabolism 
Epidemiology and Demographics of Prostatitis
Jan Roigas  European Urology Supplements 
Volume 76, Issue 2, Pages (July 2009)
Michael Marberger  European Urology Supplements 
Presentation transcript:

Testosterone Associations with Erectile Dysfunction, Diabetes, and the Metabolic Syndrome  T. Hugh Jones  European Urology Supplements  Volume 6, Issue 16, Pages 847-857 (October 2007) DOI: 10.1016/j.eursup.2007.07.002 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Prevalence of hypogonadism in men with type 2 diabetes. Incidence of positive symptom score in men with low testosterone by decades of age. (A) Total testosterone (TT). , TT < 8nmol/l; , TT < 12nmol/l. (B) Bioavailable testosterone (BT) and calculated free testosterone (cFT). , BT<2.5nmol/l; , BT<4nmol/l; , cFT<0.255nmol/l. © (2007) American Diabetes Association From Diabetes Care, Vol. 33 (2007); pages 911–917. European Urology Supplements 2007 6, 847-857DOI: (10.1016/j.eursup.2007.07.002) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Correlation of total and bioavailable testosterone levels with erectile dysfunction as assessed by IIEF scores. From ref. [38]. © (2007) International Journal of Andrology, Online early articles doi:10.1111/j.1365-2605.2007.00744x. European Urology Supplements 2007 6, 847-857DOI: (10.1016/j.eursup.2007.07.002) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 The hypogonadal-obesity-adipocytokine cycle. Increasing abdominal obesity leads to increased activity of the enzyme aromatase, present in adipose tissue, which converts testosterone to oestrogen. The resulting low testosterone level increases lipoprotein lipase enzyme activity and triglyceride uptake leading to increased obesity and insulin resistance. This in turn causes further androgen deficiency and visceral fat deposition. Oestradiol inhibits gonadotrophin release from the pituitary. Furthermore, testosterone levels are also lowered as a result of leptin resistance at the hypothalamic-pituitary level and the inhibitory effect of leptin on the testicular axis. Proinflammatory adipocytokines such as tumour necrosis α (TNF-α) and interleukin 6 (IL-6) could also potentially inhibit the pituitary axis resulting in low testosterone levels. This represents a form of secondary hypogonadism where the hypothalamic-pituitary axis cannot respond to low circulating testosterone levels. European Urology Supplements 2007 6, 847-857DOI: (10.1016/j.eursup.2007.07.002) Copyright © 2007 European Association of Urology Terms and Conditions